Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies

[1]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[2]  A. Italiano,et al.  Phase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC) , 2019, Annals of Oncology.

[3]  S. Loi,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. , 2017, The New England journal of medicine.

[4]  G. Mills,et al.  Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. , 2019, Cancer cell.

[5]  G. Mills,et al.  Adaptive responses in a PARP inhibitor window of opportunity trial illustrate limited functional interlesional heterogeneity and potential combination therapy options , 2019, Oncotarget.

[6]  G. Mills,et al.  Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. , 2019, The Lancet. Oncology.

[7]  B. Xu,et al.  OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[9]  S. Ramaswamy,et al.  Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models , 2019, Scientific Reports.

[10]  A. Ashworth,et al.  PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer , 2019, The Journal of clinical investigation.

[11]  G. Mills,et al.  Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient–Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness , 2019, Molecular Cancer Therapeutics.

[12]  P. Fasching,et al.  A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO) , 2018, Clinical Cancer Research.

[13]  G. Mills,et al.  Implementing a comprehensive translational oncology platform: from molecular testing to actionability , 2018, Journal of Translational Medicine.

[14]  G. Freeman,et al.  PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer , 2018, Cell reports.

[15]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[16]  P. Elvin,et al.  Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response , 2018, Molecular Cancer Therapeutics.

[17]  Sean C. Bendall,et al.  A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging , 2018, Cell.

[18]  M. Robson,et al.  Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases. , 2018 .

[19]  G. Mills,et al.  PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. , 2018, Cancer research.

[20]  Sandro Santagata,et al.  Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes , 2018, eLife.

[21]  Gary Middleton,et al.  Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. , 2018, Cancer discovery.

[22]  Jill A. Madden,et al.  Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition , 2018, Molecular Cancer Research.

[23]  G. Mills,et al.  BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. , 2018, Cancer cell.

[24]  Y. Bang,et al.  Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC) , 2018 .

[25]  B. Elenbaas,et al.  MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models , 2018, Oncotarget.

[26]  A. Glas,et al.  The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting , 2017, Breast Cancer Research.

[27]  D. Berry,et al.  DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial , 2017, npj Breast Cancer.

[28]  M. Robson,et al.  Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation , 2017, The New England journal of medicine.

[29]  G. Mills,et al.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.

[30]  Wenjun Chang,et al.  Androgen receptor inhibitor–induced “BRCAness” and PARP inhibition are synthetically lethal for castration-resistant prostate cancer , 2017, Science Signaling.

[31]  Adam A. Margolin,et al.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.

[32]  G. Hortobagyi,et al.  PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression , 2017, Clinical Cancer Research.

[33]  James S. Duncan,et al.  Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex. , 2017, Cancer discovery.

[34]  G. Mills,et al.  Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  P. Sorger,et al.  Cyclic Immunofluorescence (CycIF), A Highly Multiplexed Method for Single‐cell Imaging , 2016, Current protocols in chemical biology.

[36]  J. Xu,et al.  The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer , 2016, International journal of biological sciences.

[37]  Sanghui Park,et al.  Expression patterns of GATA3 and the androgen receptor are strongly correlated in patients with triple-negative breast cancer. , 2016, Human pathology.

[38]  James S. Duncan,et al.  Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer. , 2016, Cell reports.

[39]  D. Lee,et al.  Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells , 2016, PloS one.

[40]  Peter K. Sorger,et al.  Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method , 2015, Nature Communications.

[41]  Michael S. Goldberg,et al.  The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. , 2015, Biochemical and biophysical research communications.

[42]  Gordon B Mills,et al.  Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[43]  Sung-Won Kim,et al.  A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients , 2014, BMC Cancer.

[44]  Prahlad T. Ram,et al.  A pan-cancer proteomic perspective on The Cancer Genome Atlas , 2014, Nature Communications.

[45]  E. Winer,et al.  A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. , 2013, European journal of cancer.

[46]  P. Pandolfi,et al.  Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. , 2012, Cancer discovery.

[47]  Lei He,et al.  PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. , 2012, Cancer discovery.

[48]  L. Zitvogel,et al.  The secret ally: immunostimulation by anticancer drugs , 2012, Nature Reviews Drug Discovery.

[49]  Li Zhang,et al.  Serial dilution curve: a new method for analysis of reverse phase protein array data , 2009, Bioinform..

[50]  Luke Hughes-Davies,et al.  A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. , 2008, Neoplasia.

[51]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[52]  J. Goecks,et al.  High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers. , 2020, Methods in enzymology.

[53]  G. Mills,et al.  Using Reverse Phase Protein Array (RPPA) to Identify and Target Adaptive Resistance. , 2019, Advances in experimental medicine and biology.

[54]  G. Mills,et al.  Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. , 2017, American journal of cancer research.